KNSA // Kiniksa Pharmaceuticals International plc (Class A)

DES <GO> NASDAQ RQD COCKPIT → CIK 0001730430 ↗

Health Care • Biotechnology: Pharmaceutical Preparations

$90.80 ▼ -1.44 (-1.56%)

MKT CAP: $7.25B • VOL: 999.0K

52W L $37 52W H $98

ROARABLE / RQD

B- • 71/100

ALTMAN Z

24.45 SAFE

PIOTROSKI

9 / 9

KNSA // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 71/100 [B-] (+0 PT) • UNCHANGED AS OF 2026-11-03

ROARABLE B-

RQD CONFIDENCE

71 / 100 +0D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Buy — Sound Institutional Accumulation

01 MASSIVE / SEC XBRL

Forensic Fundamentals

15 / 20

SOLID

FCF +200% vs NI +200% • ROIC-WACC +0.1% • Z 24.45

02 INSTITUTIONAL TAPE & TREND

Whale & Options Flow

18 / 20

STRONG

52W RANGE 90% • VS 200D +51.1% • RSI 59.2

03 SEC XBRL CAPITAL ALLOCATION

Insider & Capital Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

14 / 20

SOLID

TAILWIND • r(10Y)=-0.12 (+19bp) • r(OAS)=-0.13

05 10-K REDLINE AUDIT

Forensic 10-K Risk

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

ALERT

Why did KNSA's Insider & Capital Conviction & Forensic 10-K Risk sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever KNSA is Upgraded or Downgraded.

KNSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.58%▲ ASCENDING CHANNEL

2026-11-03O $97.56H $97.56L $90.80C $90.80VOL 1.32M

RES: $99.76SUP: $71.73SMA50: $80.13SMA200: $61.05

KNSA // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

UNDERWEIGHT CONVICTION: 42/100

BEAR 0

100 BULL

Kiniksa Pharmaceuticals International plc (Class A) (KNSA) exhibits 88.5% gross margins and 9.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 95.0x enterprise multiple and 4.8% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 88.5% gross profitability converts into 11.4% operating margin and 9.9% ROIC, outpacing sector cost of capital.

ROIC: 9.9% // GM: 88.5%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +60.1% paired with 1.78% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +60.1% // FCF YLD: 1.78%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 24.45 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.

ALTMAN Z: 24.45 // F-SCORE: 9/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 129.9x trailing P/E (109.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 129.9x // EV/EBITDA: 95.0x

02. Options Skew & Event Volatility Risk

Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $90.80 max pain.

IMPL MOVE: ±5.2% // P/C: 0.85

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.7% net margins.

NET MARGIN: 8.7% // D/E: 0.15x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 109.1x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.11).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 129.9x

FORWARD P/E 109.1x

EV / EBITDA 95.0x

FCF YIELD 1.78%

GROSS MARGIN 88.5%

OPERATING MARGIN 11.4%

NET MARGIN 8.7%

ROIC % 9.9%

REV GROWTH YOY +60.1%

DILUTED EPS TTM $0.75

DEBT / EQUITY 0.15x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 59.2

5Y EQUITY BETA 1.11

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // KNSAPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $83.09

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for KNSA & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

KNSA VS LLY

MARGINS ROIC VALUATION

KNSA VS JNJ

MARGINS ROIC VALUATION

KNSA VS ABBV

MARGINS ROIC VALUATION

KNSA VS MRK

MARGINS ROIC VALUATION